- Home
- SAVA vs TGE Comparison
SAVA vs TGE Comparison
Compare SAVA & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- TGE
- Stock Information
- Founded
- SAVA 1998
- TGE 2023
- Country
- SAVA United States
- TGE France
- Employees
- SAVA N/A
- TGE N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- TGE Newspapers/Magazines
- Sector
- SAVA Health Care
- TGE Consumer Discretionary
- Exchange
- SAVA Nasdaq
- TGE Nasdaq
- Market Cap
- SAVA 102.4M
- TGE 120.2M
- IPO Year
- SAVA N/A
- TGE N/A
- Fundamental
- Price
- SAVA $3.63
- TGE $2.12
- Analyst Decision
- SAVA Hold
- TGE
- Analyst Count
- SAVA 1
- TGE 0
- Target Price
- SAVA $2.00
- TGE N/A
- AVG Volume (30 Days)
- SAVA 4.9M
- TGE 1.1M
- Earning Date
- SAVA 11-06-2025
- TGE 02-12-2020
- Dividend Yield
- SAVA N/A
- TGE N/A
- EPS Growth
- SAVA N/A
- TGE N/A
- EPS
- SAVA N/A
- TGE 1.64
- Revenue
- SAVA N/A
- TGE $77,014,000.00
- Revenue This Year
- SAVA N/A
- TGE N/A
- Revenue Next Year
- SAVA N/A
- TGE N/A
- P/E Ratio
- SAVA N/A
- TGE $1.28
- Revenue Growth
- SAVA N/A
- TGE 81.03
- 52 Week Low
- SAVA $1.15
- TGE $1.93
- 52 Week High
- SAVA $33.98
- TGE $37.02
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- TGE N/A
- Support Level
- SAVA $2.85
- TGE N/A
- Resistance Level
- SAVA $3.66
- TGE N/A
- Average True Range (ATR)
- SAVA 0.34
- TGE 0.00
- MACD
- SAVA 0.10
- TGE 0.00
- Stochastic Oscillator
- SAVA 92.90
- TGE 0.00
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.